Corcept Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Corcept Therapeutics Incorporated is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of selective cortisol modulators. Founded in 1998 and headquartered in Redwood City, California, the company sits at the intersection of rare endocrinology and specialty oncology. Its commercial foundation is built on Korlym (mifepristone), an FDA-approved oral medication for hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing's syndrome. Corcept is actively transitioning into a multi-asset platform company, leveraging its proprietary portfolio of selective cortisol modulators that target the glucocorticoid receptor (GR) without affinity for the progesterone receptor (PR). This includes its newly approved oncology drug Lifyorli (relacorilant) for platinum-resistant ovarian cancer, which launched in early 2026.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Commercializing and scaling the newly approved Lifyorli (relacorilant) plus nab-paclitaxel regimen for platinum-resistant ovarian cancer, including securing preferred status in clinical guidelines (such as NCCN Guidelines).
Expected impact: Establishes a second major commercial product line, diversifying revenue beyond the core Cushing's syndrome business.
Transitioning and optimizing the Cushing's syndrome distribution network to a new specialty pharmacy vendor to resolve previous capacity constraints and meet rising patient demand for Korlym.
Expected impact: Enables the company to fully satisfy market demand, leading to record-high patient starts in March and April 2026.
Implementing centralized digital systems to manage global clinical trials and automating Quality Management Systems (QMS) to ensure GxP compliance across development and manufacturing.
Expected impact: Improves oversight of extensive clinical portfolios, accelerates data pipelines, and ensures robust regulatory compliance.